Treatment options for the specific phobias

Jarnail Singh, Janardhan Singh


Specific phobias are among the most common psychological problems both in men and women. For treatment of specific phobias, exposure-based therapy is the first choice followed by cognitive therapy, relaxation techniques and short-term pharmacotherapy. Long-term pharmacotherapy for specific phobias, is associated with adverse drug reactions and drug abuse, thus not a reasonable choice for long-term symptom control. Glucocorticoids and d-cycloserine (DCS) cause fear reduction when used in combination with exposure based therapy. Being a non-anxiolytic DCS accelerates fear reduction during exposure by facilitating memory consolidation during post-treatment phase. Adjuvant cortisol to exposure therapy also caused great reduction in fear in spider phobia.


Specific phobia, Exposure-based therapy, DCS, Glucocorticoids

Full Text:



Diagnostic and Statistical Manual of Mental Disorders (DSM).2000. Available at Accessed on 21 December 2015.

Kendlar KS, Myers J, Presscott CA, Neale MC. The genetic epidemiology of irrational fears and phobias in men. Archives General Psychology. 2001;58:257-67.

Mayo Clinic Staff. Phobias. Available at http:// phobias/ basics/ treatment /con -20023478?p.Accessed on 21 December 2015.

Specific phobias. Available at http://www. Accessed on 26 December 2015.

Page AC. Blood-injury phobia. Clinical Psychology Rev. 1994;14:443-61.

Curtis GC, Hill EM, Lewis JA. Heterogeneity of DSM-III-R simple phobia the simple phobia/agoraphobia boundary: evidence from the ECA study. Report to DSM-IV anxiety disorders work group. University of Michigan. Ann Arbor, MI. 1990.

Phobias, Part 2: Specific and social phobias. Available at htpp://www.mdhill/phobias-part-2specific-and-social-phobias. Accessed on 23 December 2015.

Psych Central Staff. Specific Phobia Symptoms. Available at: http:// www. /disorders/ specific-phobia-symptoms. Accessed on 23 December 2015.

Kessler RC, Chiu WT, Demler O. Prevalence, severity and co-morbidity of 12 month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005;62:617-27.

Lindesay J, Briggs K, Murphy E. The guys/age concern survey: prevalence rate of cognitive impairment, depression and anxiety in an urban elderly community. British Journal of Psychiatry. 1989;155:317-29.

Fredrikson M, Annas P, Fischer H. Gender and age differences in the prevalence of specific fears and phobias. Behaviour research and therapy. 1996;34:33-9.

Fyer AJ, Mannuzza S, Chapman TF. Specificity in familial aggregation of phobic disorders. Arch General Psych. 1995;52:564-73.

Kendler KS, Neale MC, Kessler RC. The genetic epidemiology of phobias in women: the interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia. Arch General Psych. 1992;49:273-81.

Brown TA, Campbell LA, Lehman CL, Grisham JR, Mancill RB. Current and life comorbidity of the DSM-IV anxiety and mood disorders in a large clinical sample. Journal Abnormal Psych. 2001;110:585-99.

Wittchen HU, Nelson CB, Lachner G. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychological Medicine. 1998;28:109-26.

Magee WJ, Eaton WW, Wittchen HU. Agoraphobia, simple phobia, and social phobia in the national comorbidity survey. Arch General Psych. 1996;53:59-68.

Marks IM. Fears, phobias, and rituals: panic, anxiety, and their disorders. Oxford University Press, London;1987.

Ost LG, Salkovskis PM, Hellstrom K. One-session therapist-directed exposure vs self-exposure in treatment of spider phobia. Behavior Therapy. 1991;22:407-22.

Carlin AS, Hoffman HG, Weghorst H. Virtual reality and tactile augmentation in the treatment of spider phobia: a case report. Behaviour Research and Therapy. 1997;35:153-8.

Rothbaum BO, Anderson P, Zimand P, Hodges L, Lang D, Wilson J. Virtual reality exposure therapy and standard in vivo exposure therapy in the treatment of fear of flying. Behavioral Therapy. 2006;37(1):80-90.

Craske MG, Rowe MK. A comparison of behavioral and cognitive treatments for phobias. In GCL Davey (ed.). Phobias: A handbook of theory, research and treatment. Chichester: Wiley;1997:247-280.

Choy Y, Fyer AJ, Lipsitz JD. Treatment of specific in adults. Clinical Psychology Review. 2007;27:266-86.

23. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: A meta-analysis. Clinical Psychology Reviews 2008; 28: 1021-37.

Natural treatment for phobia and anxiety. Available at http:// /naturaltreatmentforphobiasandanxiety/ Accessed on 24 December 2015.

Adrian P. Phobic disorders treatment and management. Available at http:// /article/ 288016-treatment. Accessed on 24 December 2015.

Antony MM, Barlow DH. Specific phobias. In anxiety and its disorders: The nature and treatment of anxiety and panic. 2nd edition. Barlow DH (eds.).Guilford Press, New York; 2002.

Wilhelm FH, Roth WT. Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther. 1997;35(9):831-41.

Thom A, Sartory G, Johren P. Comparison between one-session psychological treatment and benzodiazepine in dental phobia. Journal of Consulting Clinical Psychology. 2000;68(3):378-87.

Moscovitch DA, Antony MM, Swinson RP. Exposure based treatments for anxiety disorders: theory and process. Antony MM, Stein MB (eds.), Oxford handbook of anxiety and related disorders. New York: Oxford University Press;2009:461-475.

Campos PE, Solyom L, Koelink A. The effects of timolol maleate on subjective and psysiological components of air travel phobia. Canadian Journal of Psychiatry. 1984;29:570-74.

Almay S, Zhang W, Varia I, Davidson JRT, Connor KM. Escitalopram in specific phobia: Results of a placebo controlled pilot trial. Journal of Psychopharmacology. 2008;22:157-61.

Waxman D. The management of phobic disorders using clomipramine (Anafranil). J Int Med Res. 1977;5(1):24-31.

Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P. Double blind placebo controlled pilot study of paroxetine for specific phobia. Psychopharmacology. 2000;149:194-96.

Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry. 2008;63:1118-26.

Quervian DJ, Bentz D, Michael T. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci. 2011;108:662-25.

Quervian DJ, Aerni A, Shelling G. Glucocorticoids and the regulation of memory in health and disease. Frontiers Neuroendocrinol . 2009;30:358-70.

Buchanan TW, Lovallo WR, Enhanced memory for emotional material following stress-level cortisol treatment in humans. Psycho Neuroendocrinology. 2001;26:307-17.

Candyce DT, Pamela RH, Lindsey BD, David R, Mark HP, Stefan GH. Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res. 2013;47(2):168-74.

Smits JA, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biological Psychiatry. 2013;73(11):1054-8.

Helga R, Ivan F, Alessandra L, Raquel G, Mauro VM, Evandro SFC, Paula V. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. Plos One. 2014;9(7):e93519.

Liela MS, Markus H, Livia W, Melanie F, Wolfgang S, Helge H. Glucocorticoids enhance in vivo exposure-based therapy of spider phobia. Depression and anxiety. 2014;31(5):429-35.

Quervian DJ, Jurgen M. Glucocorticoids for the treatment of post-traumatic stress disorder and phobias: A novel therapeutic approach. European Journal of Pharmacology. 2008;583:365-71.

Hood KH, Antony MM. In Intensive One-session treatment of specific phobias, Autism and Child Psychopathology Series, TE Davis III.Springer Science+Bussiness Media LLC; 2012:19-42.